Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS databas
- PDF / 880,398 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 129 Views
ORIGINAL ARTICLE
Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS‑HEALS database Joungyoun Kim1 · Hyeong‑Jin Hyun2 · Eun‑A. Choi3 · Yonghwan Kim4 · Yoon‑Jong Bae1 · Hee‑Taik Kang4,5 Received: 17 February 2020 / Accepted: 10 May 2020 © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2020
Abstract Background Diabetes mellitus (DM) increases atherosclerotic cardiovascular complications and cancer risks. Stomach cancer is the most common cancer in Korea. Although the survival rate of stomach cancer has improved, the disease burden is still high. Methods This retrospective study investigated the association between metformin use and stomach cancer incidence in a Korean population using the National Health Insurance Service-National Health Screening Cohort database. Participants aged 40–80 years old at the baseline period (2002–2003) were enrolled. The study population was categorized into three groups of metformin non-users with DM, metformin users with DM, and individuals without DM (No DM group). Results A total of 347,895 participants (14,922 metformin non-users, 9891 metformin users, and 323,082 individuals without DM) were included in the final analysis. The median follow-up duration was 12.70 years. The estimated cumulative incidence of stomach cancer was highest in metformin non-users and lowest in the No DM group (men vs. women: 3.75 vs. 1.97% in metformin non-users, 2.91 vs. 1.53% in metformin users, and 2.54 vs. 0.95% in the No DM group). Compared with metformin non-users, the hazard ratios (95% confidence intervals) for stomach cancer incidence of metformin users and the No DM group were 0.710 (0.579–0.870) and 0.879 (0.767–1.006) in men and 0.700 (0.499–0.981) and 0.701 (0.544–0.903) in women, respectively, after full adjustment. Conclusions Metformin users with DM in the Korean population were at lower risk of stomach cancer incidence after controlling for potential confounding factors. Keywords Metformin · Diabetes mellitus · Stomach neoplasm · Incidence
Introduction Hyeong-Jin Hyun and Joungyoun Kim as the co-first authors equally contributed to this work Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10120-020-01085-1) contains supplementary material, which is available to authorized users. * Hee‑Taik Kang [email protected] 1
Department of Information and Statistics, Chungbuk National University, 1 Chungdae‑ro, Seowon‑gu, Cheongju, Chungbuk 28644, Republic of Korea
2
Department of Statistics, Seoul National University, Seoul 08826, Republic of Korea
3
Division of Allergy and Chronic Respiratory Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, 187, Osongsaengmyeong 2‑ro, Osong‑eup, Heungdeok‑gu, Cheongju, Chungbuk 28159, Republic of Korea
Malignant neoplasms are the leading cause of death in Korea, and among them, stomach cancer is the most common [1].
Data Loading...
